中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

109 records (took 0.06 seconds)

    THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION
    2.
    发明公开
    THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION 审中-公开

    公开(公告)号：US20230212148A1

    公开(公告)日：2023-07-06

    申请号：US18061150

    申请日：2022-12-02

    Applicant: Gilead Sciences, Inc.

    Inventor： Gediminas J. Brizgys ,  Chienhung Chou ,  Hang Chu ,  Julie Farand ,  Michael Graupe ,  Tezcan Guney ,  Darryl Kato ,  Jiayao Li ,  John O. Link ,  James B.C. Mack ,  Dong Min Mun ,  Scott D. Schroeder ,  William J. Watkins ,  Qiaoyin Wu ,  Jennifer R. Zhang

    IPC: C07D401/14 ,  C07F9/6558 ,  A61K45/06

    CPC classification number: C07D401/14 ,  C07F9/65583 ,  A61K45/06

    Abstract: Background: HIV capsid (CA) is an emerging target for antiretroviral treatment PF-3450074 (P74) is a small-molecule CA binder that has been proposed to inhibit reverse transcription (RT) by accelerating HIV core uncoating. PF74 antiviral potency can depend on cyclophilin A (CypA) binding to CA in some cells and it shares a CA binding site with the host nuclear transport factor CPSF6, which restrict HIV infection when mislocalized to the cell cytoplasm. Here we further interrogate the mechanism of action (MOA) for PF74 in human T cells and clarify its potential dependence on CypA and CPSF6.
    Methodology: HIV reporter viruses were produced in HEK293T cells and used to infect MT2 cells and primary CD4+ T cells to determine the antiviral effect of PF74. Compound exposure was controlled by staggered addition and cell washing at various times post-infection. DNA products of infection were analyzed by qPCR. CypA and CPSF6 levels were varied in MT2 cells by overexpression and shRNA knockdown. CA (P90A, N74D) and CPSF6 (FG50,AA) mutations were used to eliminate CypA or CPSF6 binding to the viral capsid. CPSF6 binding to CA was tested using a CA-NO pull down assay.
    Results: PF74 efficiently inhibited late (EC50=795 nM) and early (EC50=264 nM) post-entry stages of HIV-1 replication in single-round infectivity assays and stabilized CA-NC polymers in vitro. Stable CypA knockdown or mutation of the CypA binding site of CA (P90A) had no effect on HIV infectivity or PF74 antiviral potency in T cells. CypA-independence of PF74 MOA was confirmed in PBMCs using HIV isolates unable to bind CypA due to CA polymorphisms. Drug washout studies showed that at high concentrations (100× EC50), PF74 inactivates cell-free virus via core disassembly and also acts concomitant with the RT step in infected cells. At 10× EC50, however, PF74 acted post-RT and was not virucidal, suggesting antiviral mechanism(s) beyond capsid destabilization. In time-of-addition studies, PF74 (10× EC50) remained active when added after RT but before vDNA integration, and normal levels of late-RT products but reduced 2-LTR circles were observed under these conditions. In contrast, reduced late-RT products were detected at higher compound concentrations. Although PF74 did compete with CPSF6 binding to CA in vitro, it remained active against the N740 mutant virus that does not bind CPSF6, suggesting a CPSF6-independent MOA.
    Conclusions: Although PF74 can accelerate viral capsid disassembly at high concentrations, our results indicate that this compound primarly acts after the RT step, but prior to 2-LTR circle accumulation in human T cells, via a CypA- and CPSF6-independent MOA. We propose that by directly stabilizing the viral capsid at lower drug concentrations, PF74 may interfere with nuclear targeting of the pre-integration complex.

Patent Agency Ranking